Cargando…
RF21 | PSAT93 Improvement of Final Height in Congenital Adrenal Hyperplasia Patients Treated With Recombinant Growth Hormone
: Final height (FH) in congenital adrenal hyperplasia (CAH) patients is frequently under -1.5 SDS in relation to the normal population, even in those with good compliance, chronic androgen exposure or supraphysiological glucocorticoid doses could corroborate to this finding. Recombinant human growt...
Autores principales: | Costa, Fernanda C, de Sousa, Donaldt L, Madureira, Guiomar, Mathias, Patrícia M B R, Mendonca, Berenice B, Miranda, Mirela C, Silva, Mylena C M, Bachega, Tânia A S S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624678/ http://dx.doi.org/10.1210/jendso/bvac150.281 |
Ejemplares similares
-
PSAT072 Clinical Features of Patients with 21-Hydroxylase Deficiency and Testicular Adrenal Rest Tumors
por: Bachega, Tânia A S S, et al.
Publicado: (2022) -
SUN-361 Reproductive Outcomes in Females with Virilizing Forms of Congenital Adrenal Hyperplasia
por: Falcao, Camila, et al.
Publicado: (2019) -
SUN-172 A False Positive Result in Newborn Screening for Congenital Adrenal Hyperplasia (CAH) in a Girl with Beckwith Wiedemann Syndrome
por: Braga, Barbara Leitao, et al.
Publicado: (2020) -
RF09 | PSAT70 Comparison of Prednisolone Versus Modified-release Hydrocortisone (Efmody) in the Treatment of Congenital Adrenal Hyperplasia (CAH)
por: Merke, Deborah P, et al.
Publicado: (2022) -
PSAT028 Congenital Adrenal Hyperplasia with Adrenal Myelolipoma: Gender Identity and Choice of Therapy
por: Kasina, Siva Kumar, et al.
Publicado: (2022)